MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward INDPositive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1Obesity Treatment Candidate Designed to Preserve Lean Body Mass
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling StudiesCompletion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development
